This trial will compare the quality of life for patients with newly diagnosed MM who respond well to initial treatment, between those who receive the standard maintenance therapy (lenalidomide) and those who receive daratumumab as maintenance therapy.
1 Primary · 1 Secondary · Reporting Duration: 3 years
100 Total Participants · 2 Treatment Groups
Primary Treatment: Questionnaires · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: